Faculty Summaries
Erica A. Golemis, PhD
Erica A. Golemis, PhD
  • Deputy Chief Scientific Officer
  • Co-Leader, Molecular Therapeutics
Office Phone: 215-728-2860
Lab Phone: 215-728-3885
Fax: 215-728-3616
Office: W406

Targeting signaling networks to improve therapy

  • The molecular basis for resistance to targeted anti-cancer agents
  • Interactions of the oncogenes NEDD9 and Aurora-A kinase in cancer and polycystic kidney disease.
  • Targeting HSP90 to improve therapy: new strategies.
  • Defining the underlying basis for cancer risk.
Description of research projects
Selected Publications
  1. Plimack, E., R., Dunbrack, R.L., Brennan, T., Andrake, M, Zhou, Y., Serebriiskii, I.G., Wei, Q., Slifker, M., Alpaugh, K., Dulaimi, E., Palma, N., Hoffman-Censits, J., Wong, Y.-N., Bilusic, M., Kutikov, A., Viterbo, R., Greenberg, R.E., Chen, D., Lallas, C.D., Trabulsi, E.J., Yelensky, R., McConkey, D., Miller, V.A., Golemis, E.A., and Ross, E.G. Alterations in ATM, Rb1 or FANCC predict response to neoadjuvant cisplatin based chemotherapy in muscle invasive bladder cancer. Europ Urol, Epub July 31 2015. PubMed
  2. Little, J.L., Serzhanova, V., Izumchenko, E., Egleston, B.L., Parise, E., Klein-Szanto, A.J., Loudon, G., Shubina, M., Seo, S., Kurokawa, M., Ochs, M.F., and Golemis, E.A. A requirement for Nedd9 in luminal progenitor cells prior to mammary tumorigenesis in MMTV-HER2/ErbB2 mice. Oncogene, 33:411-420, 2014. PubMed
  3. Nikonova, A.S., Serzhanova, V., Plotnikova, O.V., Efimov, A., Bogush, I., Cai, K.Q., Egleston, B.L., Klein-Szanto, A.S., Seeger-Nukpezah, T.N., and Golemis, E.A. Nedd9 restrains renal cystogenesis in Pkd1-/- mice.  Proc Nat Acad Sci 111:12859-64, 2014. PubMed
  4. Sukhanova, A., Gorin, A., Serebriiskii, I.G., Gabitova, L., Zheng, H., Restifo, D., Egleston, B., Cunningham, D., Bagnyukova, T., Liu, H., Nikonova, A., Adams, G.P., Zhou, Y., Yang, D., Mehra, R., Burtness, B., Cai, K.Q., Klein-Szanto, A., Kratz, L.E., Kelley, R.I., Weiner, L.M., Herman, G.E., Golemis, E.A., and Astsaturov, I. Targeting C4-demethylating genes in the cholesterol pathway sensitizes cancer cells to EGFR inhibitors via increased EGFR degradation.  Cancer Discovery, Jan;3(1):96-111. doi: 10.1158/2159-8290.CD-12-0031, 2013. PubMed
  5. Seeger-Nukpezah, T., Proia, D.A., Egleston, B.L., Nikonova, A.S., Kent, T., Cai, K.Q., Hensley, H.H., Ying, W., Chimmanamada, D., Serebriiskii, I.G., and Golemis, E.A. A novel Hsp90 inhibitor slows cyst growth in a mouse model of autosomal dominant polycystic kidney disease (ADPKD). Proc. Nat. Acad Sci. 110:12786-91, 2013. PubMed
  6. Liu, H., Xiao, F., Serebriiskii, I.G., O’Brien, S.W., Maglaty, M.A., Astsaturov, I.A., Litwin, S., Martin, L.P., Proia, D.A., Golemis, E.A. and Connolly, D.C. Network analysis identifies an HSP90-central hub susceptible in ovarian cancer.  Clin Cancer Res, 19:5053-5057, 2013.
  7. Plotnikova, O.V., Nikonova, A.S., Pugacheva, E.N., and Golemis, E.A. Calmodulin activation of Aurora-A (AURKA) is required during ciliary disassembly and in mitosis. Mol Biol Cell 23:2658-70, 2012. PubMed
  8. Li, Y., Bavarva, J.H., Wang, Z., Guo, J. Qian, C., Thibodeau, S.N., Golemis, E.A., and Liu, W.  HEF1, a novel target of Wnt signaling, promotes colonic cell migration and cancer progression. Oncogene 30:2633-43, 2011. PubMed
  9. Plotnikova, O.V., Pugacheva, E.P., and Golemis, E.A., Aurora-A kinase activity influences calcium signaling in kidney cells. J. Cell Biol 193:1021-1032, 2011. PubMed
  10. Ratushny, V., Pathak, H.B., Beeharry, N., Tikhmyanova, N., Li, T., Litwin, S., Yen, T.J., Weiner, L.M., Godwin, A.K., and Golemis, E.A. Dual inhibition of SRC and Aurora kinases induces post-mitotic attachment defects and cell death.  Oncogene 31(10):1217-27, 2012 Epub Jul 25, 2011. PubMed
  11. Astsaturov, I., Ratushny, V., Sukhanova, A., Einarson, M., Bagnyukova, T., Zhou, Y., Devarajan, K., Silverman, J.S., Tikhmyanova, N., Skobeleva, N., Pecherskaya, A., Nasto, R., Jablonski, S.J., *Serebriiskii, I.G., *Weiner, L.M., and *Golemis, E.A. Synthetic lethal screen of an EGFR-centered signaling network defines clusters of proteins contributing to drug resistance. *co-corresponding.  Science Signaling, 3(140):ra67, 2010.
  12. Plotnikova, O.V., Pugacheva, E.N., Dunbrack, R.L., Jr., and Golemis E.A. Rapid calcium-dependent activation of Aurora-A kinase. Nature Commun. 1(6):1-8: 64 doi: 10.1038/ncomms1061, 2010. PubMed
  13. Singh, M.K., Izumchenko, E., Klein-Szanto, A., Egleston, B.L., Wolfson, M., Golemis, E.A.  Enhanced genetic instability and dasatinib sensitivity in mammary tumor cells lacking Nedd9. Cancer Research 70:8907-8916, 2010. PubMed
  14. Izumchenko, E., Singh, M.K., Plotnikova, O.V., Tikhmyanova, N., Little, J.L., Serebriiskii, I.G., Seo, S., Kurokawa, M., Egleston, B.L., Klein-Szanto, A., Pugacheva, E.N., Hardy, R.R., Wolfson, M., Connolly, D.C., and Golemis, E.A. HEF1/CAS-L/NEDD9 null status limits mouse mammary tumor progression.  Cancer Research 61:7198-206, 2009. PubMed
  15. Pugacheva, E.N., Jablonski, S.A., Hartman, T.R., Henske, E.P, and Golemis, E.A. HEF1-dependent Aurora A activation induces disassembly of the primary cilium. Cell129:1351-1363, 2007. PubMed
All publications